Released Jun 14, 2024, after the close
10-Q filed Jun 14, 2024, 45 days after period end · 0001654954-24-007794
Q2 2024 · 10-Q
Revenue$2.38M$2.38M −47.9% vs Q2 2023−0.1% vs Q1 2024
Net Income-$213.82K-$213.82K N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.01-$0.01 no prior Q2 2023 on fileN/M vs Q1 2024
Gross Profit$618,475−54.1%
Operating Income-$313,375N/M
Operating Cash Flow-$700,744N/M
Free Cash Flowderived-$700,744N/M
Margins · derived
Gross margin26.0%−3.5 pt vs Q2 2023
Operating margin-13.2%−21.5 pt vs Q2 2023
Net margin-9.0%−17.9 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $2.38M | $4.56M | $4.97M | $5.04M |
| Net Income | -$213.82K | $404.65K | $240.03K | $240.27K |
| EPS Diluted | -$0.01 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR